Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $53.45, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ARCALYST; Concentration risk — Geographic: United States.
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST as its sole approved product, treating recurrent pericarditis in the US and generating substantially all revenue there. US profits on ARCALYST are split evenly with Regeneron; pipeline includes... Read more
Sell if holding. At $53.45, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ARCALYST; Concentration risk — Geographic: United States. Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Score 6.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, news boost analyst cluster(3), earnings proximity 89d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARCALYST10-K Item 1A: 'We are currently only authorized to market ARCALYST, our sole product, for the treatment of recurrent pericarditis in the United States, where we derive substantially all of our revenue.'
- HIGHGeographicUnited States10-K Item 1A: 'where we derive substantially all of our revenue. Our future growth may depend, in part, on our ability to commercialize our current and future products in markets outside of the United States'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $53.45, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ARCALYST; Concentration risk — Geographic: United States. Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Prior stop was $49.28. Score 6.2/10, moderate confidence.
Take-profit target: $54.38 (+2.6% upside). Prior stop was $49.28. Stop-loss: $49.28.
Concentration risk — Product: ARCALYST; Concentration risk — Geographic: United States; Analyst target reached - limited upside remaining.
Kiniksa Pharmaceuticals Interna trades at a P/E of 58.2 (forward 35.9). TrendMatrix value score: 4.7/10. Verdict: Sell.
14 analysts cover KNSA with a consensus score of 4.3/5. Average price target: $63.
What does Kiniksa Pharmaceuticals Interna do?Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST as its sole approved product,...
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST as its sole approved product, treating recurrent pericarditis in the US and generating substantially all revenue there. US profits on ARCALYST are split evenly with Regeneron; pipeline includes KPL-387 (Phase 2/3) and KPL-1161 (pre-clinical).